Viracta Therapeutics, Inc. (VIRX) Misses Q2 EPS by 3c

Viracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q2 EPS of ($0.32), $0.03 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Scotiabank Reiterates Sector Outperform Rating on Ero Copper Corp. (ERO:CN) (ERO)
• TD Cowen on Alaska Air (ALK): 'Can Alaska ReAccelerate?'